GPT and type 2 diabetes mellitus: Notably, participants with T2D-MAFLD, as compared to the other two subgroups, had significantly higher NFS (p=0.002), CAP (p<0.001) and LS measurements (p<0.001) despite similar serum ALT levels (Table 1).